

## **Global Allergic Conjunctivitis Treatment Market Report and Forecast 2023-2031**

Market Report | 2023-04-10 | 147 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

### **Report description:**

Global Allergic Conjunctivitis Treatment Market Report and Forecast 2023-2031

Global Allergic Conjunctivitis Treatment Market Outlook

The growth of the global allergic conjunctivitis treatment market is being driven by the increasing prevalence of the condition worldwide and the growing investment in research and development activities. The global allergic conjunctivitis treatment is likely to grow at a rate of 6.2% during the forecast period of 2023-2031.

#### **Allergic Conjunctivitis Treatment Market: Introduction**

Allergic conjunctivitis is a common eye condition caused by allergens, such as pollen, dust, and animal dander. The condition is characterized by inflammation of the conjunctiva, leading to symptoms such as redness, itching, and watery discharge. Treatment options for allergic conjunctivitis include antihistamines, mast cell stabilizers, and corticosteroids. The global allergic conjunctivitis treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments.

The market is also expected to benefit from the increasing investment in research and development activities by key players in the industry. The development of novel therapies and the increasing focus on personalized medicine are likely to create new growth opportunities for the market players. Furthermore, the expanding healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to contribute to the growth of the market.

#### **Allergic Conjunctivitis Epidemiology**

Allergic conjunctivitis is a common eye condition that affects people of all ages worldwide. It is caused by an allergic reaction to an irritant or allergen, such as pollen, dust mites, pet dander, or mould.

The prevalence of allergic conjunctivitis varies based on factors such as geography, climate, and seasonal changes. According to a report by the American Academy of Ophthalmology, allergic conjunctivitis affects approximately 20% of the population. In the United States, it is estimated that about 6 million people are affected by allergic conjunctivitis each year. The condition can affect people of all ages, but it is more common in children and young adults. Studies have shown that the prevalence of allergic

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

conjunctivitis is higher in urban areas compared to rural areas.

Additionally, people who have a history of allergies or atopic conditions such as eczema, asthma, and allergic rhinitis (hay fever) are more likely to develop allergic conjunctivitis. The risk of developing allergic conjunctivitis also increases with exposure to allergens and irritants, such as cigarette smoke, pollution, and chemicals. Early diagnosis and appropriate treatment are crucial in managing allergic conjunctivitis and preventing complications.

#### Allergic Conjunctivitis Treatment Market Segmentations

The market can be categorised into diagnosis method, treatment method, and therapeutic channel.

##### Market Breakup by Diagnosis Method

- Prenatal Testing
- ?□Amniocentesis
- ?□Chorionic Villus Sampling
- Physical Exam
- Blood and Urine Tests
- Genetic Testing

##### Market Breakup by Treatment Method

- Medication
- Medications
- Physical Exams
- Reconstructive Surgery

##### Market Breakup by Therapeutic Channel

- Public
- Private

##### Market Breakup by Region

- North America
- ?□United States of America
- ?□Canada
- Europe
- ?□United Kingdom
- ?□Germany
- ?□France
- ?□Italy
- ?□Others
- Asia Pacific
- ?□China
- ?□Japan
- ?□India
- ?□ASEAN
- ?□Australia
- ?□Others
- Latin America
- ?□Brazil
- ?□Argentina
- ?□Mexico
- ?□Others
- Middle East and Africa
- ?□Saudi Arabia
- ?□United Arab Emirates

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ? Nigeria
- ? South Africa
- ? Others

#### Allergic Conjunctivitis Treatment Market Scenario

The increasing prevalence of the disease, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.

North America dominates the allergic conjunctivitis treatment market, followed by Europe and Asia Pacific. The high prevalence of allergic conjunctivitis in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for allergic conjunctivitis treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

#### Key Players in the Global Allergic Conjunctivitis Treatment Market

The report gives an in-depth analysis of the key players involved in the allergic conjunctivitis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Sun Pharmaceutical Industries Limited
- Novartis AG
- Bausch & Lomb
- AbbVie Inc.
- Ocular Therapeutic, Inc.
- Alexion Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- Dr. Reddy's Laboratories Ltd.
- Alembic Pharmaceuticals Ltd.
- Grevis Pharmaceuticals Pvt. Ltd.

#### Table of Contents:

- 1 Preface
  - 1.1 Objectives of the Study
  - 1.2 Key Assumptions
  - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Allergic Conjunctivitis Overview
  - 4.1 Guidelines and Stages
  - 4.2 Pathophysiology
  - 4.3 Screening and Diagnosis
  - 4.4 Treatment Pathway
- 5 Patient Profile
  - 5.1 Patient Profile Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2 Patient Psychology and Emotional Impact Factors
- 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework
  - 6.1 Emerging Therapies and Clinical Trials
  - 6.2 Patent Landscape
    - 6.2.1 Patent Overview
      - 6.2.1.1 Patent Status and Expiry
      - 6.2.1.2 Timelines from Drug Development to Commercial Launch
      - 6.2.1.3 New Drug Application
        - 6.2.1.3.1 Documentation and Approval Process
  - 6.3 Cost of Treatment
  - 6.4 Regulatory Framework
    - 6.4.1 Regulatory Overview
      - 6.4.1.1 US FDA
      - 6.4.1.2 EU EMA
      - 6.4.1.3 INDIA CDSCO
      - 6.4.1.4 JAPAN PMDA
      - 6.4.1.5 Others
- 7 Challenges and Unmet Needs
  - 7.1 Treatment Pathway Challenges
  - 7.2 Compliance and Drop-Out Analysis
  - 7.3 Awareness and Prevention Gaps
- 8 Global Allergic Conjunctivitis Treatment Market
  - 8.1 Global Allergic Conjunctivitis Treatment Market Overview
  - 8.2 Global Allergic Conjunctivitis Treatment Market Analysis
    - 8.2.1 Market Overview
      - 8.2.1.1 Global Allergic Conjunctivitis Treatment Market Historical Value (2016-2022)
      - 8.2.1.2 Global Allergic Conjunctivitis Treatment Market Forecast Value (2023-2031)
  - 8.3 Global Allergic Conjunctivitis Treatment Market by Diagnosis
    - 8.3.1 Market Overview
      - 8.3.1.1 Allergy Skin Test
      - 8.3.1.2 Blood Test
      - 8.3.1.3 Others
  - 8.4 Global Allergic Conjunctivitis Treatment Market by Drug Class
    - 8.4.1 Market Overview
      - 8.4.1.1 Antihistamines and Mast Cell Stabilisers
      - 8.4.1.2 Corticosteroids
      - 8.4.1.3 NSAIDS
      - 8.4.1.4 Others
  - 8.5 Global Allergic Conjunctivitis Treatment Market by Disease Type
    - 8.5.1 Market Overview
      - 8.5.1.1 Seasonal Allergic Conjunctivitis
      - 8.5.1.2 Contact Conjunctivitis
      - 8.5.1.3 Giant Papillary Conjunctivitis
      - 8.5.1.4 Perennial Conjunctivitis
      - 8.5.1.5 Vernal Keratoconjunctivitis
      - 8.5.1.6 Atopic Keratoconjunctivitis

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.6 Global Allergic Conjunctivitis Treatment Market by Treatment Channel
  - 8.6.1 Market Overview
    - 8.6.1.1 Public
    - 8.6.1.2 Private
- 8.7 Global Allergic Conjunctivitis Treatment Market by Region
  - 8.7.1 Market Overview
    - 8.7.1.1 North America
    - 8.7.1.2 Europe
    - 8.7.1.3 Asia Pacific
    - 8.7.1.4 Middle East and Africa
    - 8.7.1.5 Latin America
- 9 North America Allergic Conjunctivitis Treatment Market
  - 9.1 Market Share by Country
  - 9.2 United States of America
    - 9.2.1 Historical Trend (2016-2022)
    - 9.2.2 Forecast Trend (2023-2031)
  - 9.3 Canada
    - 9.3.1 Historical Trend (2016-2022)
    - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Allergic Conjunctivitis Treatment Market
  - 10.1 Market Share by Country
  - 10.2 United Kingdom
    - 10.2.1 Historical Trend (2016-2022)
    - 10.2.2 Forecast Trend (2023-2031)
  - 10.3 Germany
    - 10.3.1 Historical Trend (2016-2022)
    - 10.3.2 Forecast Trend (2023-2031)
  - 10.4 France
    - 10.4.1 Historical Trend (2016-2022)
    - 10.4.2 Forecast Trend (2023-2031)
  - 10.5 Italy
    - 10.5.1 Historical Trend (2016-2022)
    - 10.5.2 Forecast Trend (2023-2031)
  - 10.6 Others
- 11 Asia Pacific Allergic Conjunctivitis Treatment Market
  - 11.1 Market Share by Country
  - 11.2 China
    - 11.2.1 Historical Trend (2016-2022)
    - 11.2.2 Forecast Trend (2023-2031)
  - 11.3 Japan
    - 11.3.1 Historical Trend (2016-2022)
    - 11.3.2 Forecast Trend (2023-2031)
  - 11.4 India
    - 11.4.1 Historical Trend (2016-2022)
    - 11.4.2 Forecast Trend (2023-2031)
  - 11.5 ASEAN
    - 11.5.1 Historical Trend (2016-2022)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 11.5.2 Forecast Trend (2023-2031)
- 11.6 Australia
  - 11.6.1 Historical Trend (2016-2022)
  - 11.6.2 Forecast Trend (2023-2031)
- 11.7 Others
- 12 Latin America Allergic Conjunctivitis Treatment Market
  - 12.1 Market Share by Country
  - 12.2 Brazil
    - 12.2.1 Historical Trend (2016-2022)
    - 12.2.2 Forecast Trend (2023-2031)
  - 12.3 Argentina
    - 12.3.1 Historical Trend (2016-2022)
    - 12.3.2 Forecast Trend (2023-2031)
  - 12.4 Mexico
    - 12.4.1 Historical Trend (2016-2022)
    - 12.4.2 Forecast Trend (2023-2031)
  - 12.5 Others
- 13 Middle East and Africa Allergic Conjunctivitis Treatment Market
  - 13.1 Market Share by Country
  - 13.2 Saudi Arabia
    - 13.2.1 Historical Trend (2016-2022)
    - 13.2.2 Forecast Trend (2023-2031)
  - 13.3 United Arab Emirates
    - 13.3.1 Historical Trend (2016-2022)
    - 13.3.2 Forecast Trend (2023-2031)
  - 13.4 Nigeria
    - 13.4.1 Historical Trend (2016-2022)
    - 13.4.2 Forecast Trend (2023-2031)
  - 13.5 South Africa
    - 13.5.1 Historical Trend (2016-2022)
    - 13.5.2 Forecast Trend (2023-2031)
  - 13.6 Others
- 14 Global Allergic Conjunctivitis Treatment Market Dynamics
  - 14.1 Market Drivers and Constraints
  - 14.2 SWOT Analysis
  - 14.3 Porter's Five Forces Model
  - 14.4 Key Demand Indicators
  - 14.5 Key Price Indicators
  - 14.6 Industry Events, Initiatives & Trends
  - 14.7 Value Chain Analysis
- 15 Supplier Landscape
  - 15.1 Sun Pharmaceutical Industries Limited
    - 15.1.1 Company Overview
    - 15.1.2 Product Portfolio
    - 15.1.3 Demographic Reach and Achievements
    - 15.1.4 Mergers and Acquisitions
    - 15.1.5 Certifications

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.2 Novartis AG
  - 15.2.1 Company Overview
  - 15.2.2 Product Portfolio
  - 15.2.3 Demographic Reach and Achievements
  - 15.2.4 Mergers and Acquisitions
  - 15.2.5 Certifications
- 15.3 Bausch & Lomb
  - 15.3.1 Company Overview
  - 15.3.2 Product Portfolio
  - 15.3.3 Demographic Reach and Achievements
  - 15.3.4 Mergers and Acquisitions
  - 15.3.5 Certifications
- 15.4 AbbVie Inc.
  - 15.4.1 Company Overview
  - 15.4.2 Product Portfolio
  - 15.4.3 Demographic Reach and Achievements
  - 15.4.4 Mergers and Acquisitions
  - 15.4.5 Certifications
- 15.5 Ocular Therapeutix, Inc.
  - 15.5.1 Company Overview
  - 15.5.2 Product Portfolio
  - 15.5.3 Demographic Reach and Achievements
  - 15.5.4 Mergers and Acquisitions
  - 15.5.5 Certifications
- 15.6 Alexion Pharmaceuticals Inc.
  - 15.6.1 Company Overview
  - 15.6.2 Product Portfolio
  - 15.6.3 Demographic Reach and Achievements
  - 15.6.4 Mergers and Acquisitions
  - 15.6.5 Certifications
- 15.7 Santen Pharmaceutical Co., Ltd.
  - 15.7.1 Company Overview
  - 15.7.2 Product Portfolio
  - 15.7.3 Demographic Reach and Achievements
  - 15.7.4 Mergers and Acquisitions
  - 15.7.5 Certifications
- 15.8 Dr. Reddy's Laboratories Ltd.
  - 15.8.1 Company Overview
  - 15.8.2 Product Portfolio
  - 15.8.3 Demographic Reach and Achievements
  - 15.8.4 Mergers and Acquisitions
  - 15.8.5 Certifications
- 15.9 Alembic Pharmaceuticals Ltd.
  - 15.9.1 Company Overview
  - 15.9.2 Product Portfolio
  - 15.9.3 Demographic Reach and Achievements
  - 15.9.4 Mergers and Acquisitions

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.9.5 Certifications
- 15.10 Grevis Pharmaceuticals Pvt. Ltd.
  - 15.10.1 Company Overview
  - 15.10.2 Product Portfolio
  - 15.10.3 Demographic Reach and Achievements
  - 15.10.4 Mergers and Acquisitions
  - 15.10.5 Certifications
- 16 Global Allergic Conjunctivitis Treatment Market- Drug Distribution Model (Additional Insight)
  - 16.1 Overview
  - 16.2 Potential Distributors
  - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
  - 17.1 Government Funded
  - 17.2 Private Insurance
  - 17.3 Out-of-Pocket



## Global Allergic Conjunctivitis Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-10 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-12"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com